Bladder cancer stage I with cancer in situ – Diagnostics – Overview of Information and Clinical Research

Diagnosing bladder cancer, especially stage I with carcinoma in situ, requires careful evaluation to catch the disease when it’s most treatable and to guide appropriate treatment decisions. Understanding which tests are needed, when to seek them, and what they reveal about your cancer can help you take an active role in your care.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing symptoms that might indicate bladder cancer should speak with their doctor promptly about diagnostic testing. The most common warning sign is hematuria, which means blood in the urine. This blood may make your urine appear pink, red, or brownish, though sometimes the amount is so small it can only be detected through laboratory tests. Blood in the urine doesn’t always appear consistently—you might notice it one day and then have weeks or even months of clear urine before it returns.^[5]

Other symptoms that should prompt you to seek diagnostic evaluation include changes in how your bladder functions. You might experience painful urination, needing to urinate much more frequently than usual, feeling a sudden and urgent need to urinate, or having urine leak unexpectedly. Even though stage I bladder cancer with carcinoma in situ is an early-stage disease, these irritating urinary symptoms are surprisingly common with this type of cancer. This happens because carcinoma in situ can cause inflammation and irritation in the bladder lining, even though the cancer hasn’t grown deep into the bladder wall.^[3]

Adults aged 35 years and older who have blood in their urine detected on testing should undergo a complete evaluation for bladder cancer. Younger adults should also be evaluated if they have visible blood in the urine, irritating bladder symptoms, or known risk factors for bladder cancer such as smoking, chemical exposure at work, or a family history of the disease.^[13]

⚠️ Important

Blood in the urine should never be ignored, even if it comes and goes. While many conditions can cause this symptom, it’s important to rule out bladder cancer through proper testing. Early detection significantly improves treatment outcomes, so don’t delay seeking medical attention if you notice this symptom.

Classic Diagnostic Methods

When bladder cancer is suspected, your doctor will use several diagnostic approaches to confirm whether cancer is present, determine its exact type, and understand how far it has spread. The diagnostic process typically begins with simpler tests and progresses to more detailed examinations if needed.

Physical Examination and Medical History

Your doctor will start by taking a detailed medical history, asking about your symptoms, how long you’ve had them, and any risk factors you might have. This includes questions about smoking, occupational exposures to chemicals, previous treatments with certain medications, and family history of cancer. A physical examination may include a digital rectal exam, where the doctor inserts a gloved finger into the rectum to feel for any abnormalities in the bladder wall or nearby organs.^[5]

Urinalysis and Urine Tests

Laboratory testing of your urine is an essential part of the diagnostic process. A standard urinalysis can detect blood cells, signs of infection, and other abnormalities that might explain your symptoms. However, it’s important to know that a urine dipstick test alone—the quick test that changes color when dipped in urine—should not be used as the only method to diagnose blood in the urine. If the dipstick suggests blood is present, your doctor should confirm this with a microscopic examination of the urine.^[13]

Urine cytology is another laboratory test where your urine sample is examined under a microscope to look for cancer cells. This test is particularly good at detecting high-grade cancers and carcinoma in situ, with a sensitivity greater than 90 percent for these aggressive tumor types. Because of its high accuracy for detecting serious bladder cancers, urine cytology can be especially helpful when there’s a high suspicion of disease. However, routine use of this test for everyone with bladder symptoms is not recommended because it may not detect all types of bladder cancer.^[13]

Testing for specific substances in the urine, called tumor markers, is available but should not be performed routinely as part of initial bladder cancer evaluation. These tests look for certain proteins or genetic material that cancer cells might release into the urine, but they are not reliable enough on their own to diagnose or rule out bladder cancer.^[13]

Cystoscopy: The Gold Standard

The most important diagnostic test for bladder cancer is cystoscopy. During this procedure, a urologist inserts a thin, flexible tube called a cystoscope through your urethra and into your bladder. The cystoscope has a tiny light and camera at its tip, allowing the doctor to directly view the inside lining of your bladder on a video screen. This direct visualization lets the doctor see any abnormal areas, growths, or flat patches that might indicate cancer.^[11]

Cystoscopy should be performed in all patients with visible blood in the urine, all patients 35 years and older who have microscopic blood detected on testing, and all patients with irritating bladder symptoms that cannot be explained by other causes, regardless of age. This procedure is essential because it allows the doctor to see exactly where abnormalities are located and what they look like.^[13]

If the doctor sees suspicious areas during cystoscopy, they can collect small tissue samples through the same tube. This is called a biopsy. The tissue samples are then sent to a laboratory where a pathologist examines them under a microscope to determine whether cancer cells are present, what type of cancer it is, and how abnormal the cells appear.^[11]

Transurethral Resection: Diagnosis and Treatment Combined

For patients with bladder cancer, the procedure called transurethral resection, or TUR, serves both diagnostic and therapeutic purposes. Like cystoscopy, this procedure is performed through the urethra, so no external incisions are needed. During TUR, the urologist not only looks at the bladder lining but also removes visible tumors using instruments passed through the scope. The surgeon can use electrical current (called cautery) or laser energy to destroy cancer tissue.^[2]

This procedure is particularly important for stage I bladder cancer with carcinoma in situ because it provides critical information about how deep the cancer has grown into the bladder wall. The surgeon must ensure that the tissue sample includes part of the muscle layer beneath the tumor so the pathologist can determine whether the cancer has invaded into the muscle. If the first TUR doesn’t provide an adequate sample or doesn’t remove enough of the tumor, a repeat procedure may be necessary.^[8]

The tissue removed during TUR allows doctors to assign a grade to the cancer, which describes how abnormal the cancer cells look under the microscope. Bladder cancers are generally classified as either low grade or high grade. Carcinoma in situ is always classified as high grade, meaning the cells look very abnormal and tend to be more aggressive. This high-grade classification is one reason why carcinoma in situ, despite being an early-stage cancer confined to the bladder lining, requires careful monitoring and aggressive treatment.^[3]

Imaging Tests

Imaging studies help doctors see the upper parts of the urinary system, including the kidneys and ureters (the tubes that carry urine from the kidneys to the bladder). Initial evaluation for bladder cancer should include imaging of the upper urinary tract because cancer cells can sometimes be found in multiple locations throughout the urinary system.^[13]

Computed tomography urography, also called CT urography, is the preferred imaging test. This specialized CT scan creates detailed three-dimensional images of your kidneys, ureters, and bladder. It involves injecting a contrast dye into your vein that travels through your bloodstream to your urinary system, making these structures clearly visible on the scan. This test can detect tumors, stones, or other abnormalities throughout the urinary tract.^[13]

Other imaging tests that might be used include ultrasound, regular CT scans, or magnetic resonance imaging (MRI). The choice depends on various factors including your kidney function (some people cannot receive CT contrast dye), what information the doctor needs, and what equipment is available.^[11]

Diagnostics for Clinical Trial Qualification

When patients with stage I bladder cancer and carcinoma in situ consider joining a clinical trial, they undergo additional diagnostic evaluations beyond the standard tests used for diagnosis. Clinical trials testing new treatments need to ensure that participants meet specific criteria so that the study results are reliable and meaningful. These qualification tests help researchers understand the exact characteristics of each participant’s cancer and overall health status.

Staging and Grading Confirmation

Clinical trials require precise documentation of your cancer’s stage and grade. This means you’ll need complete pathology reports from your transurethral resection that clearly show the cancer is confined to specific layers of the bladder wall and hasn’t invaded into the muscle. The pathologist’s assessment must confirm both the presence of stage I disease (cancer that has grown into the connective tissue beneath the bladder lining but not into the muscle) and carcinoma in situ (flat, high-grade cancer on the surface of the bladder lining).^[4]

Because stage I with carcinoma in situ is considered high-risk bladder cancer due to its aggressive nature and tendency to recur or progress, clinical trials often specifically target patients with this combination of features. Researchers use this risk classification—low risk, intermediate risk, high risk, or very high risk—to match patients with appropriate experimental treatments.^[8]

Assessment of Previous Treatments

Many clinical trials for bladder cancer want to know whether you’ve received previous treatments and how your cancer responded. For non-muscle-invasive bladder cancer including stage I with carcinoma in situ, this often means documenting whether you’ve had intravesical therapy—medications placed directly into the bladder. The most common intravesical treatment is BCG (bacillus Calmette-Guérin), which is a type of immunotherapy that stimulates your immune system to attack cancer cells.^[6]

Some clinical trials specifically enroll patients whose cancer has not responded to BCG therapy, a situation called BCG failure. Other trials might be looking for patients who haven’t yet received any treatment beyond the initial tumor removal. Your medical records need to clearly document your treatment history, including when treatments were given, how many doses you received, and whether your cancer recurred after treatment.^[6]

Follow-up Cystoscopy Results

Clinical trials typically require recent cystoscopy results showing the current status of your bladder. Because bladder cancer, particularly carcinoma in situ, has a high tendency to recur, regular cystoscopy examinations are part of standard follow-up care. Trial investigators need to know whether you currently have visible tumors, how many tumors are present, their sizes and locations, and whether carcinoma in situ is still detected. These repeat cystoscopy examinations might be performed with biopsies of normal-appearing bladder tissue to check for carcinoma in situ that isn’t visible to the eye.^[16]

Performance Status and Overall Health

Beyond cancer-specific tests, clinical trials assess your overall health and ability to function in daily life. This is often measured using standardized scales called performance status scores. Doctors evaluate whether you can care for yourself, how much time you spend in bed or resting, and whether you’re able to work or do your usual activities. These assessments help researchers determine if you’re healthy enough to tolerate the experimental treatment being studied.

Clinical trials also typically require blood tests to check your kidney function, liver function, and blood cell counts. Because many bladder cancer treatments can affect these organs and systems, researchers need baseline measurements before starting any experimental therapy. These tests help ensure that participants are not at excessive risk for complications from the trial treatment.

Documentation Requirements

All of these diagnostic findings must be thoroughly documented in your medical records. Clinical trials have strict requirements for the types and timing of tests. For example, imaging studies might need to have been performed within a certain number of weeks before enrollment, or pathology slides might need to be reviewed by the trial’s central laboratory to confirm the diagnosis. Understanding these requirements and working with your healthcare team to gather all necessary documentation is an important part of determining whether a clinical trial is right for you.

Prognosis and Survival Rate

Prognosis

The outlook for patients with stage I bladder cancer combined with carcinoma in situ depends on several important factors. This combination is classified as high-risk bladder cancer because carcinoma in situ has a greater likelihood of recurring after treatment and a higher risk of progressing to more invasive disease compared to other early-stage bladder cancers. The presence of carcinoma in situ is associated with a less favorable prognosis because it tends to come back even after treatment, and there is an increased risk that it will develop into invasive bladder cancer that grows into the muscle layer of the bladder wall.^[19]

Several factors influence the prognosis for individual patients. The number of tumors present matters—people with multiple tumors or multiple areas affected by cancer have a higher risk of recurrence compared to those with only one tumor. The size of tumors also plays a role, with smaller tumors generally having a better outlook than larger ones. How quickly cancer recurs after treatment is another important consideration. Cancers that come back within a few months after initial treatment tend to have a less favorable prognosis than those that recur many years later.^[19]

Without treatment, carcinoma in situ has a concerning natural history. Within five years of diagnosis, approximately 40 to 60 percent of patients with untreated carcinoma in situ develop invasive bladder cancer that grows into deeper layers of the bladder wall. The average risk of this progression is about 54 percent across multiple studies. However, treatment can significantly improve these outcomes. When patients with carcinoma in situ receive intravesical BCG therapy, the risk of progression decreases substantially to approximately 9.8 percent, representing a significant benefit from treatment.^[6]

Survival rate

Surgery alone, specifically transurethral resection, is effective in preventing cancer recurrence in approximately 50 percent of patients with superficial bladder cancer, which includes stage I disease. This means that about half of patients treated only with tumor removal will not experience a recurrence. For those whose cancer does come back, it usually appears as new superficial cancers that can be treated again with the same approach—transurethral resection combined with destruction of cancer tissue using electrical current or laser therapy.^[2]

Long-term survival data shows that more than half of patients who survive 15 to 20 years after initial diagnosis will have experienced either progressive cancer or, more commonly, the development of new cancers. These new cancers can occur not only in the bladder but also in other parts of the urinary tract, including the ureters (tubes connecting the kidneys to the bladder) and the renal pelvis (where the kidney connects to the ureter). Approximately 20 to 30 percent of these recurrent or new cancers will require more extensive surgery, potentially including removal of part or all of the bladder.^[2]

The depth of tumor invasion and the overall stage of cancer are crucial prognostic factors. The deeper a tumor has grown into the bladder wall, the less favorable the prognosis becomes. Stage I bladder cancer, by definition, has grown into the connective tissue layer beneath the bladder lining but has not reached the muscle layer, which places it in an intermediate position in terms of prognosis. When combined with the aggressive nature of carcinoma in situ, these cancers require close monitoring and often aggressive treatment to achieve the best possible outcomes.^[19]

#1 Clinical Trials Search in Europe